ES2170377T3 - Composicion que contiene quitosana. - Google Patents

Composicion que contiene quitosana.

Info

Publication number
ES2170377T3
ES2170377T3 ES97912239T ES97912239T ES2170377T3 ES 2170377 T3 ES2170377 T3 ES 2170377T3 ES 97912239 T ES97912239 T ES 97912239T ES 97912239 T ES97912239 T ES 97912239T ES 2170377 T3 ES2170377 T3 ES 2170377T3
Authority
ES
Spain
Prior art keywords
composition containing
quitosana
chitosan
compound
concerns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97912239T
Other languages
English (en)
Inventor
Hanno Kolbe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9612894A external-priority patent/FR2754823A1/fr
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of ES2170377T3 publication Critical patent/ES2170377T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO DE QUITOSAN QUE PRESENTA ENTRE 5 Y 300 RESIDUOS DE GLUCOSAMINA, UNA PREPARACION PRACTICAMENTE PURA DE QUITOSAN, UNA COMPOSICION QUE LO CONTIENEN ASI COMO LA UTILIZACION TERAPEUTICA DE ESTA ULTIMA PARA LA TRANSFERENCIA DE UNA SUSTANCIA TERAPEUTICAMENTE ACTIVA EN UNA CELULA HUESPED. LA PRESENTE INVENCION SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA PREPARAR TAL COMPUESTO O TAL PREPARACION.
ES97912239T 1996-10-23 1997-10-23 Composicion que contiene quitosana. Expired - Lifetime ES2170377T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9612894A FR2754823A1 (fr) 1996-10-23 1996-10-23 Nouveaux derives du chitosan, compositions comportant du chitosan ou ses derives et application de ces compositions sur le transfert d'acide nucleique dans une cellule hote
FR9702296A FR2754824B1 (fr) 1996-10-23 1997-02-26 Nouvelle composition contenant du chitosan

Publications (1)

Publication Number Publication Date
ES2170377T3 true ES2170377T3 (es) 2002-08-01

Family

ID=26233061

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97912239T Expired - Lifetime ES2170377T3 (es) 1996-10-23 1997-10-23 Composicion que contiene quitosana.

Country Status (11)

Country Link
EP (1) EP0934342B1 (es)
JP (1) JP2001502736A (es)
AT (1) ATE211489T1 (es)
AU (1) AU725723B2 (es)
CA (1) CA2268804A1 (es)
DE (1) DE69709891T2 (es)
DK (1) DK0934342T3 (es)
ES (1) ES2170377T3 (es)
FR (1) FR2754824B1 (es)
PT (1) PT934342E (es)
WO (1) WO1998017693A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069206A1 (en) * 1998-07-10 2003-04-10 Nichols Everett J. Methods and kits for absorbing fat
CN1196496C (zh) * 1999-02-25 2005-04-13 Dcv公司 干酸－壳聚糖复合物
NO317653B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
EP3000487B8 (en) 2007-02-19 2022-06-15 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
JP7821423B2 (ja) * 2021-12-17 2026-02-27 国立大学法人 東京大学 消化管腫瘍マーキング用組成物及びキット

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6121103A (ja) * 1984-07-10 1986-01-29 Yaizu Suisan Kagaku Kogyo Kk キトサンオリゴ糖の製造方法
JPS62292802A (ja) * 1986-06-12 1987-12-19 Higeta Shoyu Kk キトサンの精製法
JPH0220292A (ja) * 1988-07-06 1990-01-23 Agency Of Ind Science & Technol 低分子化キトサンの製造方法
JPH03198782A (ja) * 1989-12-27 1991-08-29 Bitamin Kenkyusho:Kk 遺伝子導入用キャリアー、該キャリアーと遺伝子との複合体及び細胞への遺伝子導入法

Also Published As

Publication number Publication date
EP0934342A1 (fr) 1999-08-11
DE69709891T2 (de) 2002-08-29
CA2268804A1 (fr) 1998-04-30
ATE211489T1 (de) 2002-01-15
PT934342E (pt) 2002-06-28
FR2754824B1 (fr) 1999-03-05
DK0934342T3 (da) 2002-04-22
EP0934342B1 (fr) 2002-01-02
JP2001502736A (ja) 2001-02-27
AU725723B2 (en) 2000-10-19
AU4950597A (en) 1998-05-15
FR2754824A1 (fr) 1998-04-24
DE69709891D1 (de) 2002-02-28
WO1998017693A1 (fr) 1998-04-30

Similar Documents

Publication Publication Date Title
TR199900083T2 (xx) Klaritromisinin kristal bi�imi I.
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
AU2977695A (en) Compositions for applying active substances to or through the skin
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
AU7619291A (en) Use of baclofen for obtaining medicaments for the treatment of angina pectoris
PL307914A1 (en) Lipopetide derivatives, method of obtaining them and therapeutic agents containing such compounds
IL114294A0 (en) Sterol derivatives
UA41355C2 (uk) Засіб для лікування нейро-сніду
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
GB9907571D0 (en) Compounds
AU1945495A (en) Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
ES2170377T3 (es) Composicion que contiene quitosana.
WO2000042987A3 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
AU2811400A (en) Stable formulation containing fumagillin
TW344650B (en) Fungicidal compositions and the process for the preparation thereof
HUP9801596A3 (en) Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
UA30250A (uk) Антиоксидантний засіб
AP9600780A0 (en) Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 934342

Country of ref document: ES